Immuneel Therapeutics introduces Qartemi, India's first personalised CAR T-cell therapy for B-NHL, offering affordable ...

Explore the journey of Georgie Swallow who was diagnosed with Stage 4 Hodgkin Lymphoma after ignoring symptoms Read ahead to ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

AstraZeneca’s (AZ) Calquence (acalabrutinib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...

A new study published in the Journal for Immunotherapy of Cancer has presented a promising advancement in chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL).

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

Investing.com -- AstraZeneca (LON: AZN) in a stock exchange filing on Friday said that the FDA approved its drug Calquence ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...